Database

You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.

Psykedeelit 2025 in Turku explores challenges in psychedelic research through keynotes and interdisciplinary dialogue, October 2025.
Published: 2025-02-15
This observational cohort study (n=450) will compare the long-term effectiveness, safety, and patient satisfaction of intravenous (IV) ketamine versus intranasal esketamine (Spravato) for treating major depressive disorder (MDD) that has not responded to at least two antidepressant trials (treatment-resistant depression, TRD).
Category: Trials
Published: 2025-02-15
This open-label, single-arm trial (n=12) will study the effects of a single dose of psilocybin (25mg) on individuals with prolonged grief disorder (PGD).
Category: Trials
Published: 2025-02-15
This Phase III, randomised, open-label trial (n=400) will compare the effectiveness, acceptability, and side effects of intravenous ketamine (60mg per dose) and intranasal esketamine (56–84mg per dose) in patients with treatment-resistant depression (TRD).
Category: Trials
Published: 2025-02-15
This open-label, interventional trial (n=10) will assess the safety and acceptability of up to two sequential doses of 25 mg psilocybin, administered with therapeutic support, in individuals with Bipolar II disorder (BD-II) depression experiencing suicidal ideation.
Category: Trials
Published: 2025-02-15
This open-label, interventional trial (n=120) will investigate the effects of intravenous ketamine (35mg/70kg over 40 minutes, maximum dose 60mg) on brain function, structure, and molecular signatures in patients with major depressive disorder (MDD).
Category: Trials
Published: 2025-02-15
This triple-blind, randomised, placebo-controlled trial (n=60) will study the role of neuroplasticity in the behavioural effects of psilocybin in individuals with mild declines in emotional wellbeing. Participants will receive one of four medication combinations, involving either 25 mg or 1 mg of psilocybin alongside intravenous (IV) midazolam or IV saline.
Category: Trials
Published: 2025-02-15
This Phase IIa, multi-centre, double-blind, randomised, placebo-controlled trial (n=60) will investigate the safety, tolerability, and efficacy of EMP-01 in adults with social anxiety disorder (SAD). Participants will be randomised 1:1 to receive two administrations of either 225 mg EMP-01 or placebo on Day 1 and Day 29, with the primary endpoint assessed at Day 43.
Category: Trials
Published: 2025-02-15
This open-label trial (n=10) will investigate the effects of a single dose of MDMA on social cognition in adults with Borderline Personality Disorder (BPD).
Category: Trials
Published: 2025-02-15
This Phase I, randomised, placebo-controlled, triple-masked, crossover design trial (n=60) will investigate the safety, tolerability, electrophysiological effects, and efficacy of dimethyltryptamine (DMT) in individuals with major depressive disorder (MDD) and healthy controls.
Category: Trials
Published: 2025-02-15

Psychedelic Database

Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.

Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.